Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Tactile Systems Technology, Inc. (TCMD), operating under the Tactile Medical brand, is a U.S.-based medical device company focused on developing and commercializing pneumatic compression therapy solutions. The company primarily serves patients with chronic lymphedema, lipedema, and other venous and lymphatic disorders, operating within the medical devices and chronic disease management industries. Its core revenue is generated from the sale and rental of advanced pneumatic compression devices prescribed for home use, with reimbursement largely driven by U.S. health insurers, including Medicare.
The company is positioned as a specialist provider in a niche segment of chronic care, emphasizing clinically validated therapy, direct clinician engagement, and patient education. Founded in the mid-1990s, Tactile Systems Technology evolved from a small medical device innovator into a publicly traded company following its initial public offering in 2016, expanding its commercial infrastructure and clinical evidence base to support broader adoption of its therapies.
Business Operations
Tactile Systems Technology operates primarily through a single reportable segment focused on pneumatic compression therapy, with its principal products including the Flexitouch and Nimbl systems marketed under the Tactile Medical business unit. Revenue is generated through device sales, consumables, and related services, supported by a direct sales force that works with prescribing clinicians and healthcare systems. The company’s operations are predominantly domestic, with the United States accounting for the vast majority of revenue.
The company controls proprietary device designs, therapy algorithms, and a patient support platform that assists with onboarding, reimbursement navigation, and adherence. A notable subsidiary asset includes the AffloVest product line, added through the acquisition of AffloVest from International Biophysics Corporation, which expanded Tactile’s presence into airway clearance therapy for patients with chronic respiratory conditions.
Strategic Position & Investments
Strategically, Tactile Systems Technology focuses on expanding its addressable market by increasing awareness and diagnosis of lymphatic disorders, broadening payer coverage, and extending indications for its existing technologies. Growth initiatives have emphasized clinical research investment, sales force expansion, and deeper penetration into underdiagnosed patient populations such as lipedema.
The company’s most significant acquisition to date remains AffloVest, which diversified its product portfolio while maintaining focus on chronic, home-based therapies. Beyond this, Tactile has prioritized organic investment in next-generation device development and digital patient engagement capabilities. Public disclosures indicate limited exposure to early-stage or non-core technologies, reflecting a strategy centered on disciplined capital allocation within adjacent therapeutic areas.
Geographic Footprint
Tactile Systems Technology is headquartered in North America, with its corporate headquarters located in Minnesota, United States. The company’s commercial and operational footprint is overwhelmingly concentrated in the U.S., where it maintains sales, clinical support, and administrative functions aligned with the domestic reimbursement environment.
International operations are limited, and while the company has evaluated opportunities outside the U.S., its current market presence across Europe, Asia-Pacific, and other regions remains minimal. International influence is primarily indirect, through clinical research visibility rather than direct commercial investment.
Leadership & Governance
Tactile Systems Technology is led by an executive team with experience in medical devices, reimbursement-driven healthcare markets, and commercial execution. The leadership philosophy emphasizes evidence-based medicine, disciplined growth, and patient-centric care delivery, as reflected in public statements and regulatory filings.
- Sheri Dodd – President and Chief Executive Officer
- Bryan Riskey – Chief Financial Officer
Public sources reference additional executive leadership roles in operations, commercial strategy, and clinical affairs; however, specific titles and role definitions vary across disclosures. Data inconclusive based on available public sources.